National Comprehensive Cancer Network
- NCCN
Guidelines®- End User License Agreement
- NCCN Guidelines for
Treatment of Cancer by Site- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Anal Carcinoma
- Basal and Squamous Cell Skin Cancers
- Bladder Cancer
- Bone Cancer
- Breast Cancer
- Central Nervous System Cancers
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colon Cancer
- Dermatofibrosarcoma Protuberans
- Esophageal and Esophagogastric Junction Cancers
- Gastric Cancer
- NCCN Guidelines for Detection,
Prevention, & Risk Reduction - NCCN Guidelines for
Supportive Care - NCCN Guidelines for
Age Related Recommendations - NCCN Guidelines for Patients™
- International Adaptations & Translations
- NCCN Pocket Guidelines
- NCCN Disclosure Policies &
Potential Conflicts of Interest - Licensing and Permissions
- Stay up-to-date with
NCCN Flash Updates™ - NCCN Mobile Applications
- NCCN
Compendium® - Educational Events
& Programs - Subscriptions
& Products- NCCN Compendium
- NCCN Templates
- Combination Subscriptions
- NCCN Flash Updates™
- NCCN Flash Updates™ Coupons
- NCCN Trends™ Surveys & Data
- NCCN Academy Video Modules
- NCCN eBulletin Newsletter
- NCCN Health Information Technology Licensees
- JNCCN — Journal of the National Comprehensive Cancer Network
- Advertising Opportunities
- NCCN Online Catalog
- Clinical & Business
Resources- Members Only
- NCCN Corporate Council
- NCCN Insights: Analytics, Research & Consulting
- NCCN Resource Tool: REMS
- NCCN Virtual Reimbursement Resource Room
- NCCN Health Information Technology Licensees
- NCCN Oncology Research Program (ORP)
- ORP Recent News
- ORP Scientific Publications
- ORP Investigator Steering Committee
- ORP Testimonials
- Clinical Trials at NCCN Member Institutions
- Find ORP Funded Clinical Trials at NCCN Member Institutions
- NCCN Specialized Imaging Research Consortium™ (SIRC)
- NCCN ORP Disclosure Policy
- NCCN ORP for Industry
NCCN Guidelines® & Clinical Resources
You must Login or Register to access this information.
NCCN Drugs & Biologics Compendium (NCCN Compendium®)
Click here to subscribe to the NCCN Compendium®
Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.
The NCCN Compendium® is now recognized by the Centers for Medicare and Medicaid Services (CMS) and UnitedHealthcare as an authoritative reference for oncology coverage policy. Managed care medical directors, pharmacy benefits directors, and other health care professionals also reference the NCCN Compendium when making decisions that impact patient access to appropriate therapy. The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation. All recommendations (at all category levels) in the NCCN Compendium constitute appropriate, medically-necessary care. The NCCN Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.
The NCCN Drugs & Biologics Compendium (NCCN Compendium®) is copyrighted by the NCCN. All rights reserved. NCCN content may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section
Table of Contents
|
Browse by Generic Name: |
You must Login or Register to access this information. |
| A |
|
| Back to Top |
| B |
|
| Back to Top |
| C |
|
| Back to Top |
| D |
|
| Back to Top |
| E |
|
| Back to Top |
| F |
|
| Back to Top |
| G |
|
| Back to Top |
| H |
|
| Back to Top |
| I |
|
| Back to Top |
| J |
|
| Back to Top |
| K |
|
| Back to Top |
| L |
|
| Back to Top |
| M |
|
| Back to Top |
| N |
|
| Back to Top |
| O |
|
| Back to Top |
| P |
|
| Back to Top |
| Q |
|
| Back to Top |
| R |
|
| Back to Top |
| S |
|
| Back to Top |
| T |
|
| Back to Top |
| U |
|
| Back to Top |
| V |
|
| Back to Top |
| W |
|
| Back to Top |
| X |
|
| Back to Top |
| Y |
|
| Back to Top |
| Z |
|
| Back to Top |
Disclaimer
The NCCN Guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to cancer treatment. The recommendations regarding the uses and indications in the NCCN Compendium have been derived directly from the NCCN Guidelines. The NCCN Compendium represents neither an all-inclusive listing of every drug and biologic nor every appropriate use and indication for drugs and biologics. The NCCN Templates are peer reviewed statements of consensus of their authors derived from the NCCN Guidelines for the conditions the NCCN Templates address. The NCCN Templates are not exhaustive and do not represent the full spectrum of care or treatment options described in the NCCN Guidelines or the NCCN Compendium or include all appropriate approaches or combinations of drugs or biologics for the treatment of cancer. A NCCN Template does not constitute an order.
Order the latest flash drive of the Complete Library of NCCN Guidelines®.
| Quick Links |
|
|
Cancers that are not included in the NCCN Drugs & Biologics Compendium® represent rare forms of cancer. The absence of such mention means only that NCCN Guidelines are not available to address these rare cancers and, thus, that no value judgment or recommendation about appropriateness or effectiveness of treatment recommendations has been rendered by NCCN. Because these are rare tumors, NCCN believes that care should be individualized. In general, NCCN recommends consulting the existing peer-reviewed medical literature to form a treatment plan for patients with rare tumors.
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved